Atorvastatin Pre-Treatment Influences the Risk of Percutaneous Coronary Intervention Study

• Status: Completed
• Trial end date: 2008-12-01
• Target enrollment: 0
• Participant gender: All

Summary

This study investigates potential protective effect of atorvastatin pre-treatment in patient with stable coronary artery disease undergoing percutaneous coronary intervention (PCI). Patient are randomized to two groups: atorvastatin pre-treatment group (80mg atorvastatin two days before PCI) and control group (PCI without atorvastatin pretreatment). Endpoint is myocardial infarction measured by troponin I and creatine kinase myocardial band.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University Hospital, Motol
• Treatments: Atorvastatin; Atorvastatin Calcium

Criteria

Inclusion Criteria:

• stable angina in last month

• indication for percutaneous coronary intervention

• informed consent

Exclusion Criteria:

• acute coronary syndrome in last 14 days

• renal insufficiency (creatinine more 150 µmol/l)

• diseases severely limiting prognosis

• immunosuppressive treatment

• statin one month before randomization

• occlusion of the coronary artery

• previous participation in this study